| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 131, 1165-1173, Copyright © 1992 by Endocrine Society
ARTICLES |
HS Hundal, T Ramlal, R Reyes, LA Leiter and A Klip
Division of Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada.
The effects of the oral hypoglycemic drug metformin on glucose and amino acid transporter activity and subcellular localization of GLUT1 and GLUT4 glucose transporters were tested in cultured L6 myotubes. In muscle cells preexposed to maximal doses of metformin (2 mM, for 16 h), 2-deoxyglucose uptake was stimulated by over 2-fold from 5.9 +/- 0.3 to 13.3 +/- 0.5 pmol/min.mg protein. Uptake of the nonmetabolizable amino acid analog methylaminoisobutyrate was unaffected by treatment with the drug under identical conditions. Extracellular calcium was required to preserve the full response to the biguanide. Exposure of muscle cells to insulin in the presence of metformin resulted in further activation of 2-deoxyglucose transport. The latter effect was additive to the maximum effect of metformin, suggesting that the biguanide stimulates hexose uptake into muscle cells by an insulin-independent mechanism. Glucose transporter number quantified by performing studies of D- glucose-protectable binding of cytochalasin-B in plasma membranes (PM) and internal membranes (IM) prepared from L6 myotubes revealed that a 16-h treatment with 800 microM metformin significantly elevated glucose transporter number in the PM (by 47%), with an equivalent decrement in glucose transporter number (47%) in the IM. Western blot analysis using antisera reactive with the GLUT1 and GLUT4 isoforms of glucose transporters showed that metformin caused a reduction in GLUT1 content in the IM fraction and a concomitant increase in the PM. Unlike insulin, metformin treatment had no effect on the subcellular distribution of GLUT4. We propose that the molecular basis of metformin action in skeletal muscle involves the subcellular redistribution of GLUT1 proteins from an intracellular compartment to the plasma membrane. Such a recruitment process may form an integral part of the mechanism by which the drug stimulates glucose uptake (and utilization) in skeletal muscle and facilitates lowering of blood glucose in the management of type II diabetes.
This article has been cited by other articles:
 |
|
 |
|
  R. Saeedi, H. L. Parsons, R. B. Wambolt, K. Paulson, V. Sharma, J. R. B. Dyck, R. W. Brownsey, and M. F. Allard Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2497 - H2506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Horvath, L. Tackett, A. M. McCarthy, P. Raman, J. T. Brozinick, and J. S. Elmendorf Antidiabetogenic Effects of Chromium Mitigate Hyperinsulinemia-Induced Cellular Insulin Resistance via Correction of Plasma Membrane Cholesterol Imbalance Mol. Endocrinol., April 1, 2008; 22(4): 937 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J.O. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells Cancer Res., November 15, 2007; 67(22): 10804 - 10812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Buzzai, R. G. Jones, R. K. Amaravadi, J. J. Lum, R. J. DeBerardinis, F. Zhao, B. Viollet, and C. B. Thompson Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth Cancer Res., July 15, 2007; 67(14): 6745 - 6752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Kim, S.-Y. Park, J.-Y. Kim, J.-Y. Huh, W.-S. Jeon, C.-J. Yoon, S.-S. Yun, and K.-H. Moon Metformin Restores the Penile Expression of Nitric Oxide Synthase in High-Fat-Fed Obese Rats J Androl, July 1, 2007; 28(4): 555 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bertrand, A. Ginion, C. Beauloye, A. D. Hebert, B. Guigas, L. Hue, and J.-L. Vanoverschelde AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H239 - H250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang and G. D. Holman Long-Term Metformin Treatment Stimulates Cardiomyocyte Glucose Transport through an AMP-Activated Protein Kinase-Dependent Reduction in GLUT4 Endocytosis Endocrinology, June 1, 2006; 147(6): 2728 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chen, P. Liu, G. R. Pattar, L. Tackett, P. Bhonagiri, A. B. Strawbridge, and J. S. Elmendorf Chromium Activates Glucose Transporter 4 Trafficking and Enhances Insulin-Stimulated Glucose Transport in 3T3-L1 Adipocytes via a Cholesterol-Dependent Mechanism Mol. Endocrinol., April 1, 2006; 20(4): 857 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Kim, J.-Y. Kim, Y.-H. Park, S.-Y. Park, K.-C. Won, K.-H. Choi, J.-Y. Huh, and K.-H. Moon Metformin Restores Leptin Sensitivity in High-Fat-Fed Obese Rats With Leptin Resistance Diabetes, March 1, 2006; 55(3): 716 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Petersen, S. Dufour, D. Befroy, M. Lehrke, R. E. Hendler, and G. I. Shulman Reversal of Nonalcoholic Hepatic Steatosis, Hepatic Insulin Resistance, and Hyperglycemia by Moderate Weight Reduction in Patients With Type 2 Diabetes Diabetes, March 1, 2005; 54(3): 603 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ten and N. Maclaren Insulin Resistance Syndrome in Children J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2526 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Gunton, P. J. D. Delhanty, S.-I. Takahashi, and R. C. Baxter Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1323 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Stadtmauer, B. C. Wong, and S. Oehninger Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hawley, A. E. Gadalla, G. S. Olsen, and D. G. Hardie The Antidiabetic Drug Metformin Activates the AMP-Activated Protein Kinase Cascade via an Adenine Nucleotide-Independent Mechanism Diabetes, August 1, 2002; 51(8): 2420 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. D. Fryer, A. Parbu-Patel, and D. Carling The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways J. Biol. Chem., July 5, 2002; 277(28): 25226 - 25232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers Metformin: An Update Ann Intern Med, July 2, 2002; 137(1): 25 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Musi, M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, et al. Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes Diabetes, July 1, 2002; 51(7): 2074 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hyde, K. Peyrollier, and H. S. Hundal Insulin Promotes the Cell Surface Recruitment of the SAT2/ATA2 System A Amino Acid Transporter from an Endosomal Compartment in Skeletal Muscle Cells J. Biol. Chem., April 12, 2002; 277(16): 13628 - 13634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-B. Kim, T. P. Ciaraldi, A. Kong, D. Kim, N. Chu, P. Mohideen, S. Mudaliar, R. R. Henry, and B. B. Kahn Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110{beta} Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects Diabetes, February 1, 2002; 51(2): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang and J. Radziuk Inverse relationship between peripheral insulin removal and action: studies with metformin Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1240 - E1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Bailey and R. C. Turner Metformin N. Engl. J. Med., February 29, 1996; 334(9): 574 - 579. [Full Text] [PDF]
|
|
|
|
 |
|
 United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years BMJ, January 14, 1995; 310(6972): 83 - 88. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
